Drug Information

Drug General Information
Drug ID
D00YPO
Former ID
DNC004302
Drug Name
TETRAHYDROBENXIMIDAZOLE
Drug Type
Small molecular drug
Indication Discovery agent Investigative [533015]
Formula
C18H20N4O
Canonical SMILES
CC1CC(=O)NN=C1C2=CC=C(C=C2)N3C=NC4=C3CCCC4
InChI
1S/C18H20N4O/c1-12-10-17(23)20-21-18(12)13-6-8-14(9-7-13)22-11-19-15-4-2-3-5-16(15)22/h6-9,11-12H,2-5,10H2,1H3,(H,20,23)
InChIKey
KDEKNYKHIZTSLE-UHFFFAOYSA-N
PubChem Compound ID
14032753
Target and Pathway
Target(s) CGMP-inhibited 3',5'-cyclic phosphodiesterase A Target Info Inhibitor [533015]
KEGG Pathway Purine metabolism
cGMP-PKG signaling pathway
cAMP signaling pathway
Morphine addiction
Reactome cGMP effects
G alpha (s) signalling events
WikiPathways miR-targeted genes in muscle cell - TarBase
miR-targeted genes in lymphocytes - TarBase
References
Ref 533015J Med Chem. 1989 Feb;32(2):342-50.Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure.
Ref 533015J Med Chem. 1989 Feb;32(2):342-50.Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure.